CureVac N.V. (CVAC) Stock Price, Financial Report, & Fundamental Analysis
NASDAQ:CVACCureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.
(1.7)
CureVac N.V. Fundamental Analysis
Strength
| Analysis | # |
|---|---|
Revenue GrowthCVAC has had growing revenue for the last 5 years |
|
Price to Book (PBV) RatioOvervalued price-to-book. CVAC stock price is overvalued by more than 1x the price-to-book value. |
|
Debt-Equity Ratio (DER)CVAC equity is higher than it's debt. |
|
RevenueCVAC has positive revenue for last 4 years |
Weakness
| Analysis | # |
|---|---|
Market CapSmall market capitalization. Market capitalization is less than 2bn USD |
|
Net Income GrowthCVAC has never had growing net income. |
|
Net IncomeCVAC never has positive net income for 2 years. |
|
Dividend YieldCVAC has low dividend yield (0%). |
|
Return of AssetsCVAC has low return of asset (-13.42%). |
|
Return of EquityCVAC has low return of equity (-18.71%). |
|
Return of Invested CapitalCVAC has low ROIC. |
Competitors
CureVac N.V. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Income Statement
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- Revenue
- 102,990,000 USD
- Cost
- 515,253,000 USD
- Net Income
- -411,716,000 USD
- Profit Margin
- -399.76%
Cashflow Statement
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -861,029,000 USD
Balance Sheet
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
| Quick Ratio | 318.9% |
Long Term Liabilities
| Liquidity/Current Ratio | 361.05% |
Dividend
| Dividend Yield | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend per Share | 0,00 USD |
Financial Ratios
| Price to Earning (PER) | -3.3x |
| Price to Earning-Growth (PEG) | 0x |
| Price to Book Value (PBV) | 0x |
| Liquidity/Current Ratio | 361.05% |
| Cash Ratio | 313.81% |
| Debt Ratio | 31.36% |
| Debt-Equity Ratio (DER) | 45.68% |
| Net Profit Margin (NPM) | -126.02% |
| Return of Assets (ROA) | -13.42% |
| Return of Equity (ROE) | -18.71% |
| Return on Capital Employed (ROCE) | -18.08% |
| Days of Sales Outstanding (DSO) | 23.23 |
| Days of Inventory Outstanding (DIO) | 16.5 |
| Days Payable Outstanding (DPO) | 110.35 |
| Operating Cycle (OC) | 22.23 |
| Cash Conversion Cycle (CCC) | -83.05 |
CureVac N.V. Executives
CEO
- CEO Name
- Dr. Franz-Werner Haas L.L.M.,
Management
CureVac N.V. Profile
About CureVac N.V.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Additional Information
- Company name
- CureVac N.V.
- Symbol
- NASDAQ:CVAC
- Exchange
- NASDAQ Global Market
- Industry
- Biotechnology
- Sector
- Healthcare
- Address
-
Friedrich-Miescher-Strasse 15
Tübingen
DE
72076 - Website
- https://www.curevac.com